The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer

NCT03154983 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Gastric Cancer

Interventions

DRUG: docetaxel

Sponsor

Zhou Fuxiang

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]